Evicenter
MarkdownMedical informationP&T meetings
Inaxaplin (VX-147)

APOL1-mediated kidney disease

Launch
Not announced
Last updated
162 sources

Executive summary

Inaxaplin efficacy and safety

4 evidence topics · 10 sources

Summary: regulatory status and pivotal trial

Inaxaplin (VX-147) is an investigational oral small-molecule inhibitor of APOL1 channel function developed by Vertex Pharmaceuticals. It has FDA Breakthrough Therapy designation and EMA PRIME designation. AMPLITUDE (NCT05312879) is an adaptive phase 2/3, randomized, double-blind, placebo-controlled trial in participants aged 10 to 65 years with two APOL1 variants, a UPCR of 0.7 to less than 10 g/g, and an eGFR of 25 to less than 75 mL/min/1.73 m2; the registry record shows 522 participants enrolled, and its phase 3 portion compares inaxaplin 45 mg once daily with placebo on top of standard of care. Vertex states that it will conduct the pre-planned interim analysis “for potential U.S. accelerated approval” after the interim analysis cohort reaches 48 weeks of treatment and share the data in early 2027. As of November 2026, no AMPLITUDE efficacy or safety results have been reported.

Summary: phase 2a study VX19-147-101

In the single-group, open-label phase 2a study, 16 participants with biopsy-proven FSGS and two APOL1 variants received inaxaplin for 13 weeks (15 mg once daily for 2 weeks, then 45 mg once daily for 11 weeks) with standard care. Among the 13 participants who met the adherence threshold, the mean change from baseline in UPCR at week 13 was -47.6% (95% CI, -60.0 to -31.3); in all 16 participants, it was -44.0% (95% CI, -56.3 to -28.3), and 1 participant had no reduction. Of the 16 participants, 15 (94%) had at least one adverse event, all mild or moderate, with no discontinuations due to adverse events. Headache (4 participants, 25%), back pain (3, 19%), and nausea (3, 19%) were the most frequent events, and 1 participant had two serious adverse events (deep-vein thrombosis and uterine leiomyoma) that the investigator considered unrelated to inaxaplin.

Summary: phase 2 study AMPLIFIED

AMPLIFIED (NCT06794996) was a single-arm, open-label study of inaxaplin 45 mg once daily added to optimized standard of care in 41 participants: cohort 1 (AMKD with modest proteinuria, n=23) and cohort 2 (AMKD with type 2 diabetes, n=18). At week 13, the geometric mean percent change in UACR was -42.7% (95% CI -58.3%, -21.1%) in cohort 1 and -17.3% (95% CI -36.3%, 7.2%) in cohort 2, and UPCR decreased by 44.7% and 25.4%, respectively; the confidence intervals were generated post hoc. No serious adverse events related to inaxaplin occurred, all adverse events were mild or moderate, headache was the most common adverse event (7.3%), and 5 participants had isolated, asymptomatic transaminase elevations that resolved.

Summary: phase 1 and clinical pharmacology studies

In two phase 1 studies in healthy adults (VX18-147-001 and VX20-147-008), 134 participants received inaxaplin and 44 received placebo. Adverse events occurred in 33 participants receiving inaxaplin (24.6%) and 10 receiving placebo (22.7%); all were mild or moderate, there were no serious adverse events, and headache occurred in 10.4% of participants receiving inaxaplin and 2.3% receiving placebo. No participant had a QTcF interval above 480 msec. In single-dose studies of 45 mg, the geometric least squares mean ratio of exposure was reported as below 120% in severe renal impairment and below 125% in mild or moderate hepatic impairment, and one participant with a Child-Pugh score of 9 had an AUC about 2.2-fold higher than participants with scores of 7 or below.